Open AccessEfficacy and safety of ibrutinib in indian patients with relapsed or refractory chronic lymphocytic leukemia and mantle cell lymphoma: Cases from a named patient program
Author(s) -
M B Agarwal,
Dinesh Bhurani,
Chirag Shah,
Nitin Sood,
Manish Singhal,
Anil Vaikunth Kamat,
Chezhian Subash,
Shuddhodan P. Mishra,
Dinesh Nagrale
Publication year - 2017
Publication title -
indian journal of medical and paediatric oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.229
H-Index - 22
eISSN - 0975-2129
pISSN - 0971-5851
DOI - 10.4103/ijmpo.ijmpo_43_17
Subject(s) - medicine , ibrutinib , mantle cell lymphoma , discontinuation , refractory (planetary science) , adverse effect , gastroenterology , chronic lymphocytic leukemia , lymphoma , surgery , leukemia , physics , astrobiology
This named patient program evaluated the safety and efficacy of ibrutinib, a selective inhibitor of Bruton's tyrosine kinase in Indian patients with relapsed/refractory chronic lymphocytic leukemia (CLL, with/without chromosome 17 deletion [del17p]) and mantle cell lymphoma (MCL).